FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

Source :: PR Newswire. October 18, 2021
Publication Year :: 2021
Abstract: LA JOLLA, Calif., Oct. 18, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs(TM)), [...]

Subjects :: United States. Food and Drug Administration
RNA
Myotonic dystrophy -- Drug therapy
Business
News, opinion and commentary

Tools